305.35
price down icon1.25%   -3.875
after-market Handel nachbörslich: 305.35 0.005 +0.00%
loading
Schlusskurs vom Vortag:
$309.22
Offen:
$308.02
24-Stunden-Volumen:
583.47K
Relative Volume:
0.94
Marktkapitalisierung:
$13.77B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
12.18
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
-0.37%
1M Leistung:
+0.28%
6M Leistung:
-5.65%
1J Leistung:
-12.57%
1-Tages-Spanne:
Value
$305.03
$312.44
1-Wochen-Bereich:
Value
$303.59
$315.73
52-Wochen-Spanne:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Firmenname
United Therapeutics Corp
Name
Telefon
(301) 608-9292
Name
Adresse
1000 SPRING ST, SILVER SPRING, MD
Name
Mitarbeiter
1,305
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
UTHR's Discussions on Twitter

Vergleichen Sie UTHR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.35 13.98B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.37 68.60B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.86 46.99B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.71 43.17B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.05 20.82B 16.70B -157.13M 1.19B -0.155

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-02 Eingeleitet Cantor Fitzgerald Overweight
2025-04-25 Herabstufung Wells Fargo Overweight → Equal Weight
2025-04-21 Hochstufung BofA Securities Underperform → Neutral
2024-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-02-12 Hochstufung Goldman Sell → Neutral
2024-02-05 Eingeleitet Leerink Partners Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2022-12-06 Eingeleitet UBS Buy
2022-12-05 Eingeleitet Goldman Sell
2022-10-11 Eingeleitet Morgan Stanley Overweight
2022-09-20 Bestätigt BofA Securities Underperform
2022-09-19 Fortgesetzt Wedbush Outperform
2022-02-11 Eingeleitet BTIG Research Neutral
2021-07-14 Hochstufung Argus Hold → Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-02-01 Hochstufung H.C. Wainwright Neutral → Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-06-25 Bestätigt H.C. Wainwright Neutral
2020-03-10 Hochstufung Jefferies Hold → Buy
2020-02-27 Hochstufung Cowen Market Perform → Outperform
2020-01-31 Hochstufung JP Morgan Neutral → Overweight
2019-12-03 Eingeleitet BofA/Merrill Underperform
2019-08-01 Hochstufung Jefferies Underperform → Hold
2019-08-01 Hochstufung Ladenburg Thalmann Neutral → Buy
2019-07-01 Hochstufung Credit Suisse Neutral → Outperform
2019-05-17 Hochstufung UBS Sell → Neutral
2019-05-09 Hochstufung Credit Suisse Underperform → Neutral
2018-10-12 Hochstufung Standpoint Research Hold → Buy
2018-08-08 Herabstufung Credit Suisse Neutral → Underperform
2018-04-03 Hochstufung Credit Suisse Underperform → Neutral
2018-02-22 Bestätigt Barclays Underweight
2018-01-18 Fortgesetzt Credit Suisse Underperform
2017-12-27 Bestätigt Wedbush Outperform
2017-04-27 Bestätigt Wedbush Outperform
2017-03-30 Eingeleitet UBS Sell
2017-03-16 Eingeleitet Credit Suisse Underperform
Alle ansehen

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

pulisher
Aug 27, 2025

Published on: 2025-08-27 13:41:12 - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

Using flow based indicators on United Therapeutics CorporationWeekly Loss Report & Weekly High Return Forecasts - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

How hedge fund analytics apply to United Therapeutics Corporation stockMarket Activity Report & Daily Profit Focused Screening - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

MannKind rises as United Therapeutics expands deal (MNKD) - Seeking Alpha

Aug 27, 2025
pulisher
Aug 27, 2025

Leading vs lagging indicators on United Therapeutics Corporation performanceDollar Strength & Capital Efficiency Focused Ideas - Newser

Aug 27, 2025
pulisher
Aug 27, 2025

MannKind Amends License Agreement with United Therapeutics - TipRanks

Aug 27, 2025
pulisher
Aug 27, 2025

United Therapeutics expands partnership with MannKind for new therapy - Investing.com

Aug 27, 2025
pulisher
Aug 27, 2025

MannKind expands collaboration with United Therapeutics, receives $5 million upfront - Investing.com

Aug 27, 2025
pulisher
Aug 27, 2025

MannKind Corporation Collaborates with United Therapeutics to Develop Second Dry Powder Inhalation Therapy - Quiver Quantitative

Aug 27, 2025
pulisher
Aug 27, 2025

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - GlobeNewswire

Aug 27, 2025
pulisher
Aug 27, 2025

How to monitor United Therapeutics Corporation with trend dashboards2025 Fundamental Recap & Consistent Profit Alerts - Newser

Aug 27, 2025
pulisher
Aug 26, 2025

United Therapeutics Corporation stock trend forecastTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Momentum divergence signals in United Therapeutics Corporation chartQuarterly Earnings Report & High Accuracy Trade Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Published on: 2025-08-26 12:14:12 - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

What’s next for United Therapeutics Corporation stock priceBear Alert & Low Drawdown Momentum Trade Ideas - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Published on: 2025-08-26 11:15:14 - Newser

Aug 26, 2025
pulisher
Aug 25, 2025

How to build a dashboard for United Therapeutics Corporation stockInsider Buying & Expert Verified Stock Movement Alerts - Newser

Aug 25, 2025
pulisher
Aug 25, 2025

Historical volatility pattern of United Therapeutics Corporation visualizedWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser

Aug 25, 2025
pulisher
Aug 23, 2025

Detecting price anomalies in United Therapeutics Corporation with AIWeekly Loss Report & Free Real-Time Market Sentiment Alerts - Newser

Aug 23, 2025
pulisher
Aug 23, 2025

Published on: 2025-08-23 04:09:17 - Newser

Aug 23, 2025
pulisher
Aug 22, 2025

Can United Therapeutics Corporation hit a new high this monthJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser

Aug 22, 2025
pulisher
Aug 19, 2025

United Therapeutics stock holds Buy rating at UBS on Tyvaso prospects - Investing.com Nigeria

Aug 19, 2025
pulisher
Aug 19, 2025

Order flow analysis tools used on United Therapeutics Corporation2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser

Aug 19, 2025
pulisher
Aug 16, 2025

Key resistance and support levels for United Therapeutics CorporationEarnings Summary Report & Reliable Intraday Trade Alerts - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - MSN

Aug 15, 2025
pulisher
Aug 14, 2025

United Therapeutics stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com

Aug 14, 2025
pulisher
Aug 13, 2025

United Therapeutics stock price target raised to $415 from $385 at UBS - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

United Therapeutics stock price target raised to $415 from $385 at UBS By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 12, 2025

United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks

Aug 12, 2025
pulisher
Aug 09, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

Should You Be Adding United Therapeutics (NASDAQ:UTHR) To Your Watchlist Today? - 富途牛牛

Aug 08, 2025
pulisher
Aug 07, 2025

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool

Aug 06, 2025
pulisher
Aug 04, 2025

H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey

Aug 04, 2025
pulisher
Aug 01, 2025

United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025

Finanzdaten der United Therapeutics Corp-Aktie (UTHR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$138.13
price up icon 0.94%
$10.42
price up icon 0.10%
drug_manufacturers_specialty_generic RDY
$14.24
price up icon 0.21%
$18.49
price up icon 3.30%
$18.05
price down icon 0.55%
Kapitalisierung:     |  Volumen (24h):